Vortex Energy Corp. ( ($TSE:VRTX) ) has issued an announcement. Vortex Energy Corp. has received government approval to conduct an Ambient Noise ...

Vertex Pharmaceuticals received a boost with Canada's approval of ALYFTREK for cystic fibrosis. This approval boosts sentiment. The stock saw a 7% rise over the past month amid broader market optimism ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.

Discover the top 10 large-cap stocks rated Buy across Seeking Alpha, Wall Street, and analyst systems, featuring strong ...

Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Key Points CRISPR Therapeutics is still in its early growth stage.Summit Therapeutics has plenty of upside potential ...

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...